AGK7
CAS No. 304896-21-7
AGK7( —— )
Catalog No. M27499 CAS No. 304896-21-7
AGK7 is an inactive control of AGK2, a selective SIRT2 inhibitor that selectively inhibits SIRT3 over SIRT1 and SIRT2 (IC50 = >5 μM, >50 μM and >50 μM for SIRT3, SIRT1, and SIRT2, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 113 | Get Quote |
|
10MG | 194 | Get Quote |
|
25MG | 409 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAGK7
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGK7 is an inactive control of AGK2, a selective SIRT2 inhibitor that selectively inhibits SIRT3 over SIRT1 and SIRT2 (IC50 = >5 μM, >50 μM and >50 μM for SIRT3, SIRT1, and SIRT2, respectively).
-
DescriptionAGK7 is an inactive control of AGK2, a selective SIRT2 inhibitor that selectively inhibits SIRT3 over SIRT1 and SIRT2 (IC50 = >5 μM, >50 μM and >50 μM for SIRT3, SIRT1, and SIRT2, respectively).(In Vitro):AGK2 is a selective SIRT2 inhibitor with IC50 value of 3.5 μM. AGK2 slightly inhibited SIRT1 and 3 only at concentrations over 40 μM. Relative to an inactive control AGK7, AGK2 increased acetylated tubulin. In H4 cells transfected with α-Syn, AGK2 reduced α-Syn-mediated toxicity in a dose-dependent way. By contrast, the inactive AGK7 had no effect. In H4 cells cotransfected withα-Syn and synphilin-1, the inactive AGK7 failed to affect a-Syn aggregation, whereas AGK2 promoted the formation of enlarged inclusions .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number304896-21-7
-
Formula Weight434.28
-
Molecular FormulaC23H13Cl2N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClc1ccc(Cl)c(c1)-c1ccc(\C=C(/C#N)C(=O)Nc2cccc3cccnc23)o1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Haar S, et al. Enhancing the Liquid-Phase Exfoliation of Graphene in Organic Solvents upon Addition of n-Octylbenzene. Sci Rep. 2015 Nov 17;5:16684.
molnova catalog
related products
-
Axillarin
Axillarin has antioxidant activity, it shows xanthine oxidase inhibitory activity ( IC(50) :36.0 uM).
-
Atropic acid
Used as a medicine, organic synthesis intermediates.
-
Cyanosafracin B
Cyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).